Mayo Clinic Researchers Find Predictive Tests and Early Treatment Delay Progression of Blood Cell Cancer

November 07, 2008

ROCHESTER, Minn. - Mayo Clinic researchers say they have moved closer to their goal of providing personalized care for a common blood cell cancer. They have found that the use of predictive biomarkers along with two targeted treatments significantly delays the need for conventional chemotherapy in patients with early-stage, but high-risk, chronic lymphoid leukemia (CLL).

Their study, published Oct. 15 in the journal Cancer, found that in a small group of patients the use of the new tools delayed the need for standard chemotherapy treatment to about four years after cancer diagnosis. Typically, people with this kind of high-risk CLL require chemotherapy at about two years after diagnosis.

Because this was a small phase II study, the researchers cannot yet say that this strategy will improve the quality or duration of life for patients. However, they say that because of these promising findings, all CLL patients at Mayo Clinic now undergo the predictive tests, whose results can be used to risk-stratify therapy, including enrollment in ongoing experimental treatments if appropriate.

The two targeted therapies studied, alemtuzumab and rituximab, are widely used in advanced-stage CLL. Both are monoclonal antibodies that produce an immune response against the cancer cells.

"This is the first publication of a study on CLL in which patients were selected for early treatment of their disease based on molecular prognostic markers, and it is also the first one to test a combination of targeted therapies in a group of patients who would not ordinarily be treated yet," says the study's lead investigator, Mayo hematologist Clive Zent, M.D.

"The standard of care for these patients is to watch and wait until patients develop more advanced disease and then to treat them with chemotherapy and monoclonal antibodies," he says. "We believe this new approach is better for patients because it identifies those who will develop aggressive CLL sooner than later and helps delay need for more toxic treatments.

"While this is a novel concept in the field of CLL treatment, we think it moves us toward the day when we can treat all patients uniquely, based on the characteristics of their individual cancer."

CLL is the most common malignancy of lymphocytes. Annually, in the United States, it is diagnosed in more than 15,000 people and results in almost 5,000 deaths. CLL is a cancer of B-lymphocytes, infection-fighting white blood cells that originate in the bone marrow. The disease progresses as the number of lymphocytes increases in bone marrow and lymph nodes and can cause patients to become ill. The rate of progression varies among patients, according to Dr. Zent. "We know that roughly one-third of patients will need treatment within two years of diagnosis, one-third will need treatment at some point in the future, and the remaining one-third of patients will never need treatment and will not die of their disease," he says.

"Because, in the past, we could never predict which patients would have more aggressive disease, we have had to watch everyone, and that requires repeated blood tests and physical exams," he says. Once the disease progresses, treatment with chemotherapy and monoclonal antibodies such as rituximab and alemtuzumab can be prescribed, but these treatments do not cure the disease.

Researchers at Mayo Clinic and other centers have developed a number of different biomarker tests to predict, with reasonable certainty, which patients are at high-, low- or moderate-risk for progression of their cancer. They have found that testing CLL cells for overproduction of CD38 and ZAP-70 proteins, and analyzing the altered state of several genes as well as chromosomal defects in the cells can significantly predict cancer that will grow faster.

In this study, Mayo investigators used the biomarkers to identify 30 early-stage CLL patients who had a 50 percent chance of needing treatment for progressive disease within two years of diagnosis and gave them a 31-day course of therapy using the two targeted treatments. They found that drug toxicities were manageable and that 90 percent of patients responded to the agent. Within this group, 11 patients had a complete response. Only nine patients required subsequent standard treatment for progressive disease at a median of 1.5 years. In contrast, time to treatment was a median of about two years in a comparison group of 117 patients who were at high risk but did not receive the targeted therapies.

"Using these tools and treatments, we hope to be able to substantially delay CLL progression in patients who are at risk," Dr. Zent says. "We don't know yet that this strategy will decrease mortality in patients, because that can only be proven in a phase III randomized clinical trial. But these good results now set the stage for such a study."

The study was funded by the National Institutes of Health-National Cancer Institute University of Iowa/Mayo Clinic Specialized Program of Research Excellence Grant. Other support came from Genentech, which co-markets Rituxan (rituximab), and from Bayer Health Care Pharmaceuticals, which markets Campath (alemtuzumab) in the U.S.

Co-authors of the study include Timothy Call, M.D.; Tait Shanafelt, M.D.; Renee Tschumper; Diane Jelinek, Ph.D.; Charla Secreto; Betsy LaPlant; Brian Kabat and Neil Kay, M.D. All are from Mayo Clinic Rochester.

Mayo Clinic

---

---

	QuickFACTS Basal and Squamous Cell Skin Cancer: What You Need to Know-NOW by American Cancer Society (Author) Complete with the most up-to-date patient treatment guidelines, this medical guide covers every aspect of basal and squamous cell skin cancer, from what the risk factors are to the benefits of early diagnosis to living healthily after treatment. Critical questions to ask the health care team are provided, as is an advanced dictionary of cancer-related terms. This pocket-sized reference aims to raise public awareness of skin cancer to promote early detection and emphasizes that all patients should be well-informed and play an active role in planning their own treatment.
	Cancer: Fight It with the Blood Type Diet (Dr. Peter J. D'Adamo's Eat Right 4 Your Type Health Library) by Dr. Peter J. D'Adamo (Author), Catherine Whitney (Author) Dr. Peter J. D'Adamo has forever changed the strategy for eating right to lose weight and achieving maximum health. Because he discovered what many already instinctively knew-that a plan that works for one person may make another ill-there will never be a one-size-fits-all diet again. And since we now know that each blood type is affected differently by common diseases and conditions, there will never be a one-size-fits-all plan of action. With more than 2 million copies of his books in print, G. P. Putnam's Sons announces the launch of Dr. D'Adamo's Eat Right 4 (for) Your Type Library. Over the next two years, eight books will be published on eight different conditions, the first two being cancer and diabetes. In these books, readers will find new information individualized...
	Stem Cells and Cancer by Sadhan Majumder (Editor) Cancer is a primary cause of human mortality worldwide. Despite decades of basic and clinical research, the outcome for most cancer patients is still dismal. Some stumbling blocks to developing effective therapy include the heterogeneity of cancer tissues, the lack of knowledge about the critical molecular mechanisms in cancer tissues (which are typically aberrant compared with mechanisms in normal tissue), and the lack of good mechanism-based therapeutic approaches. The recent findings that most cancers contain a small fraction of self-renewing, differentiation-blocked stem cell-like cells (cancer stem cells) and that it is these cells—and not the major bulk of the tissue—that are the root cause for cancer initiation and metastasis have also highlighted the need to change our...
	Defeat Cancer: 15 Doctors of Integrative & Naturopathic Medicine Tell You How by Connie Strasheim (Author), 13 Cancer Doctors (Author), Richard Linchitz MD (Introduction), Robert Rowen MD (Introduction) ONE-ON-ONE WITH 15 CANCER DOCTORS: If you traveled the world for appointments with fifteen cancer doctors, you would discover many of the cutting-edge treatments used to heal the body from cancer. You would also spend thousands of dollars on hotels, plane tickets, and medical appointment fees-not to mention the time that it would take to embark on such a journey. Even if you had the time and money to travel, would the physicians have enough time to answer all of your questions? Would you even know which questions to ask? In this long-awaited book, health care journalist Connie Strasheim has done all the work for you. She conducted intensive interviews with fifteen highly regarded doctors who specialize in cancer treatment, asking them thoughtful, important...
	Stem Cells and Cancer Stem Cells, Volume 7: Therapeutic Applications in Disease and Injury by M.A. Hayat (Editor) The seventh in Springer’s landmark series of edited volumes on one of the highest-profile subjects in contemporary medicine and scientific endeavour, this volume sets out to cover a staggering range of research into the medical applications of stem cell research. While stem cells are the very stuff of life for multicellular organisms, including us humans, the cancer stem cell is a morbid entity with a robust resistance to therapies including conventional chemotherapy. This authoritative publication explains the regenerative potential of stem cells and their mesenchymal progeny, reviewing clinical applications of the latter in the treatment of cancer, diabetes and neurodegenerative pathologies. It covers the entire range of stem cells with known potential for therapeutic use, from human...
	Hematopoietic Stem Cell Transplantation (Contemporary Hematology) by Robert J. Soiffer (Editor) Remarkable developments in the field of transplantation have created opportunities to address the formidable challenges of transplantation across histocompatibility barriers, stem cell expansion, and prevention of complications and generation of graft-vs-tumor activity to eradicate residual disease. Stem Cell Transplantation for Hematologic and Other Disorders, Second Edition provides a glimpse into potential future applications of bone marrow derived stem cells in the field of cardiac repair. The updated chapters introduce the biologic underpinnings of hematopoietic cell transplantation, basic stem cell biology, immunobiology, and histocompatibility, with emphasis on indications and results of transplantation for specific diseases. Written by experts in the field, Stem Cell...
	DNA repair capacity measured by high throughput alkaline comet assays in EBV-transformed cell lines and peripheral blood cells from cancer patients ... Toxicology and Environmental Mutagenesis] by M. Iwakawa (Author), M. Goto (Author), S. Noda (Author), M. Sagara (Author), S Yamada (Author) This digital document is a journal article from Mut.Res.-Genetic Toxicology and Environmental Mutagenesis, published by Elsevier in . The article is delivered in HTML format and is available in your Amazon.com Media Library immediately after purchase. You can view it with any web browser. Description: We collected peripheral blood (PB) from 556 patients with various types of cancer who had undergone radiotherapy and from 81 healthy volunteers. We exposed whole PB and Epstein-Barr virus-transformed lymphoblastoid cell lines (EBLs) derived from the PB mononucleocytes to X-irradiation (5Gy). Using the alkaline comet assay, we measured the immediate DNA damage and, at 15min, the % residual damage. In PB, the immediate damage was similar in patients and healthy volunteers while the...
	Patients with vitamin D deficiency fare worse in battle with lymphoma: more data needed to verify link to white blood cell cancer.: An article from: Science News by Nathan Seppa (Author) This digital document is an article from Science News, published by Science Service, Inc. on January 2, 2010. The length of the article is 576 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser. Citation Details Title: Patients with vitamin D deficiency fare worse in battle with lymphoma: more data needed to verify link to white blood cell cancer. Author: Nathan Seppa Publication: Science News (Magazine/Journal) Date: January 2, 2010 Publisher: Science Service, Inc. Volume: 177 Issue: 1 Page: 15(1) Distributed by Gale, a part of Cengage...
	In vitro screening for cytotoxic activity of the Blood Vine plant against selected cancer cell lines.(PROCEEDINGS PAPERS FROM THE MEETING)(Report): An ... from: Journal of the Idaho Academy of Science by Unavailable (Author) This digital document is an article from Journal of the Idaho Academy of Science, published by Idaho Academy of Science on June 1, 2010. The length of the article is 2017 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser. Citation Details Title: In vitro screening for cytotoxic activity of the Blood Vine plant against selected cancer cell lines.(PROCEEDINGS PAPERS FROM THE MEETING)(Report) Author: Unavailable Publication: Journal of the Idaho Academy of Science (Magazine/Journal) Date: June 1, 2010 Publisher: Idaho Academy of Science Volume: 46 Issue: 1 Page: 64(6) Article Type: Report Distributed by Gale,...
	Normal and Neoplastic Blood Cells: From Genes to Therapy (Annals of the New York Academy of Sciences) by Cesare Peschle (Editor)